User profiles for Shahriar Nafissi

Nafissi, Shahriar

Professor of Neurology, Neuromuscular Research Center, Tehran University of medical …
Verified email at sina.tums.ac.ir
Cited by 3464

[PDF][PDF] KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2

…, B Brais, GA Nicholson, H Van Esch, S Nafissi… - The American Journal of …, 2011 - cell.com
Hereditary sensory and autonomic neuropathy type II (HSANII) is a rare autosomal-recessive
disorder characterized by peripheral nerve degeneration resulting in a severe distal …

[PDF][PDF] Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect

…, CJ Mallebrera, A Nascimento, S Nafissi… - The American Journal of …, 2011 - cell.com
Neuromuscular junctions (NMJs) are synapses that transmit impulses from motor neurons to
skeletal muscle fibers leading to muscle contraction. Study of hereditary disorders of …

[HTML][HTML] COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

…, RV Do Campo, S Saba, S Nafissi… - The Lancet …, 2020 - thelancet.com
During the COVID-19 pandemic, patients with neuromuscular disorders, especially patients
with autoimmune myasthenia gravis, might be at greater risk of worse outcomes than other …

Mutation in ADORA1 identified as likely cause of early‐onset parkinsonism and cognitive dysfunction

E Jaberi, M Rohani, GA Shahidi, S Nafissi… - Movement …, 2016 - Wiley Online Library
Background We aimed to identify the genetic cause of neurological disease in an Iranian
family whose manifestations include symptoms of parkinsonism and cognitive dysfunction. …

[HTML][HTML] Recommendations for infantile-onset and late-onset Pompe disease: an Iranian consensus

…, P Sarraf, K Sayadpour Zanjani, S Nafissi - Frontiers in …, 2021 - frontiersin.org
Background: Pompe disease, also denoted as acid maltase or acid α-glucosidase deficiency
or glycogen storage disease type II, is a rare, autosomal recessive lysosomal storage …

[HTML][HTML] Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a pilot randomized clinical trial

M Ahmadi, E Agah, S Nafissi, MR Jaafari… - …, 2018 - Elsevier
The objective of present study was to assess the safety and efficacy of nanocurcumin as an
anti-inflammatory and antioxidant agent in adults with amyotrophic lateral sclerosis (ALS). …

International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r

…, S Birnbaum, JY Hogrel, S Nafissi… - Muscle & …, 2016 - Wiley Online Library
Introduction: The MG‐QOL15 is a validated, health‐related quality of life (HRQOL) measure
for myasthenia gravis (MG). Widespread use of the scale gave us the opportunity to further …

Effect of vitamin A supplementation on fatigue and depression in multiple sclerosis patients: a double-blind placebo-controlled clinical trial

…, MA Sahraian, D Soltani, S Nafissi… - Iranian Journal of …, 2016 - ijaai.tums.ac.ir
Decreasing the population and activation of inflammatory T helper cells in multiple sclerosis
(MS) patients using vitamin A derivatives (retinoic acids) has been well documented. The …

Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations

…, JJ Vilchez, N Muelas, J Kirschner, S Nafissi… - Journal of …, 2012 - Springer
Congenital myasthenic syndrome (CMS) is a clinically and genetically heterogeneous group
of inherited disorders of the neuromuscular junction. A difficult to diagnose subgroup of …

Mitochondrial complex I deficiency and ATP/ADP ratio in lymphocytes of amyotrophic lateral sclerosis patients

P Ghiasi, S Hosseinkhani, A Noori, S Nafissi… - Neurological …, 2012 - Taylor & Francis
Objectives: Several lines of evidence suggest that mitochondrial dysfunction is involved in
amyotrophic lateral sclerosis (ALS), but despite the fact that mitochondria play a central role in …